Azulenyl nitrones: neuroprotectants in stroke and trauma
甘菊硝酮:中风和创伤中的神经保护剂
基本信息
- 批准号:6669554
- 负责人:
- 金额:$ 57.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-05-02 至 2007-04-30
- 项目状态:已结题
- 来源:
- 关键词:antioxidants brain injury cerebral hemorrhage cerebral ischemia /hypoxia cooperative study disease /disorder model drug screening /evaluation high performance liquid chromatography histochemistry /cytochemistry laboratory rat magnetic resonance imaging mass spectrometry neuroprotectants nitrone pharmacokinetics stroke trauma
项目摘要
DESCRIPTION (provided by applicant):
We propose to conduct a comprehensive, milestone-driven program of translational research targeted at the validation of a novel azulenyl nitrone antioxidant compound -- stilbazulenyl nitrone (STAZN) -- as a neuroprotective therapeutic agent for three interrelated, prevalent acute neurological disorders in which reactive oxygen species contribute to tissue injury: ischemic stroke, traumatic brain injury (TBI), and parenchymal intracerebral hemorrhage (ICH). No clinically established neuroprotective therapeutic is currently available for these disorders. STAZN has the advantages of high lipophilicity and an oxidation potential within the physiologic range; it has shown great promise in pilot studies. This proposal builds upon a fruitful collaboration between the Cerebral Vascular Disease Research Center at the University of Miami and a productive laboratory of synthetic organic chemistry at Florida International University. The intent of the program is to establish a compelling body of preclinical evidence supporting the neuroprotective efficacy of STAZN as a prelude to clinical trials in stroke and trauma. Focal cerebral ischemia will be studied in rat models of both transient and permanent middle cerebral artery (MCA) suture occlusion and in recanalizable photothrombotic MCA occlusion, which engenders reperfusion injury. TBI studies will be performed in the standard moderate-to-severe fluid percussion model. Striatal intracerebral hematoma is produced by double blood injection. We shall conduct comprehensive dose-finding studies, elucidate the therapeutic time-window of efficacy, and evaluate both acute and chronic endpoints using both quantitative histopathological as well as neurobehavioral strategies. Gender- and age-related responses will be considered. Pharmacokinetic studies will document STAZN plasma curves and brain levels. The NINDS program staff has provided valuable input to us in shaping this proposal. Two world-renowned authorities in oxygen-radical biochemistry and vascular pharmacology drawn from both academia and the pharmaceutical industry will serve as External Advisors to guide us throughout this project.
描述(由申请人提供):
我们建议进行一项全面的、里程碑式的转化研究计划,目标是验证一种新型的甘菊环硝酮抗氧化剂化合物- stilbazulenyl nitrone(STAZN)-作为三种相互关联的、普遍存在的急性神经系统疾病的神经保护治疗剂,其中活性氧有助于组织损伤:缺血性中风、创伤性脑损伤(TBI)和脑实质内出血(ICH)。目前没有临床上确定的神经保护治疗可用于这些疾病。STAZN具有高亲脂性和生理范围内的氧化电位的优点;它在初步研究中显示出很大的前景。该提案建立在迈阿密大学脑血管疾病研究中心和佛罗里达国际大学合成有机化学生产实验室之间富有成效的合作基础上。该计划的目的是建立一个令人信服的临床前证据,支持STAZN的神经保护功效,作为中风和创伤临床试验的前奏。将在短暂性和永久性大脑中动脉(MCA)缝合闭塞的大鼠模型中以及在可再通的光血栓性MCA闭塞(其产生再灌注损伤)中研究局灶性脑缺血。TBI研究将在标准中度至重度液压冲击模型中进行。纹状体脑内血肿是由双重注血造成的。我们将进行全面的剂量探索研究,阐明疗效的治疗时间窗,并使用定量组织病理学和神经行为策略评估急性和慢性终点。将考虑与性别和年龄有关的答复。药代动力学研究将记录STAZN血浆曲线和脑水平。NINDS计划的工作人员在制定这一建议时为我们提供了宝贵的意见。来自学术界和制药行业的两名世界知名的氧自由基生物化学和血管药理学权威将担任外部顾问,在整个项目中指导我们。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MYRON DAVID GINSBERG其他文献
MYRON DAVID GINSBERG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MYRON DAVID GINSBERG', 18)}}的其他基金
ALIAS II/III Trial:Albumin Therapy in Ischemic Stroke
ALIAS II/III 试验:白蛋白治疗缺血性中风
- 批准号:
6796049 - 财政年份:2004
- 资助金额:
$ 57.35万 - 项目类别:
Azulenyl nitrones: neuroprotectants in stroke and trauma
甘菊硝酮:中风和创伤中的神经保护剂
- 批准号:
7064212 - 财政年份:2003
- 资助金额:
$ 57.35万 - 项目类别:
Azulenyl nitrones: neuroprotectants in stroke and trauma
甘菊硝酮:中风和创伤中的神经保护剂
- 批准号:
6744834 - 财政年份:2003
- 资助金额:
$ 57.35万 - 项目类别:
Azulenyl nitrones: neuroprotectants in stroke and trauma
甘菊硝酮:中风和创伤中的神经保护剂
- 批准号:
6877742 - 财政年份:2003
- 资助金额:
$ 57.35万 - 项目类别:
HUMAN ALBUMIN THERAPY OF ACUTE ISCHEMIC STROKE
急性缺血性中风的人白蛋白治疗
- 批准号:
6326306 - 财政年份:2001
- 资助金额:
$ 57.35万 - 项目类别:
HUMAN ALBUMIN THERAPY-TREATMENT OF ACUTE ISCHEMIC STROKE
人类白蛋白疗法-治疗急性缺血性中风
- 批准号:
6650873 - 财政年份:2001
- 资助金额:
$ 57.35万 - 项目类别:
ACUTE/SUBACUTE METABOLIC & HEMODYNAMIC TRAUMATIC BRAIN INJURY DETERMINANTS
急性/亚急性代谢
- 批准号:
6455813 - 财政年份:2001
- 资助金额:
$ 57.35万 - 项目类别:
HUMAN ALBUMIN THERAPY OF ACUTE ISCHEMIC STROKE
急性缺血性中风的人白蛋白治疗
- 批准号:
6579862 - 财政年份:2001
- 资助金额:
$ 57.35万 - 项目类别:
HUMAN ALBUMIN THERAPY-TREATMENT OF ACUTE ISCHEMIC STROKE
人白蛋白疗法-治疗急性缺血性中风
- 批准号:
6529473 - 财政年份:2001
- 资助金额:
$ 57.35万 - 项目类别:
相似海外基金
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 57.35万 - 项目类别:
Research Grant
Development of a humanised delivery system for interleukin 2 to treat traumatic brain injury
开发白细胞介素2人源化递送系统来治疗创伤性脑损伤
- 批准号:
MR/X029166/1 - 财政年份:2024
- 资助金额:
$ 57.35万 - 项目类别:
Research Grant
Blood biomarkers to detect brain injury due to intimate partner violence
血液生物标志物可检测亲密伴侣暴力造成的脑损伤
- 批准号:
486950 - 财政年份:2023
- 资助金额:
$ 57.35万 - 项目类别:
Operating Grants
Targeting Ryanodine Receptor 2 for Treating Neonatal Hypoxic-ischemic Brain Injury (HIBI)
靶向 Ryanodine 受体 2 治疗新生儿缺氧缺血性脑损伤 (HIBI)
- 批准号:
488816 - 财政年份:2023
- 资助金额:
$ 57.35万 - 项目类别:
Operating Grants
Who is Caring for the Caregiver? Understanding Quality of Life and Mental Health Outcomes in Caregivers of Persons with Brain Injury
谁在照顾看护者?
- 批准号:
492369 - 财政年份:2023
- 资助金额:
$ 57.35万 - 项目类别:
Operating Grants
A PROGRESS-Driven Approach to Cognitive Outcomes after Traumatic Brain Injury: Advancing Equity, Diversity, and Inclusion through Knowledge Synthesis and Mobilization
创伤性脑损伤后认知结果的进步驱动方法:通过知识合成和动员促进公平、多样性和包容性
- 批准号:
492338 - 财政年份:2023
- 资助金额:
$ 57.35万 - 项目类别:
Operating Grants
Advancing equity in traumatic brain injury care: A stakeholder-informed meeting on screening for traumatic brain injury in underserved populations
促进创伤性脑损伤护理的公平性:关于在服务不足的人群中筛查创伤性脑损伤的利益相关者知情会议
- 批准号:
487815 - 财政年份:2023
- 资助金额:
$ 57.35万 - 项目类别:
Miscellaneous Programs
Traumatic Brain Injury Anti-Seizure Prophylaxis in the Medicare Program
医疗保险计划中的创伤性脑损伤抗癫痫预防
- 批准号:
10715238 - 财政年份:2023
- 资助金额:
$ 57.35万 - 项目类别:
Monocyte-Derived Microglia in Development and after Neonatal Brain Injury
发育中和新生儿脑损伤后的单核细胞衍生的小胶质细胞
- 批准号:
10593385 - 财政年份:2023
- 资助金额:
$ 57.35万 - 项目类别:
Fecal Microbiota Transfer Attenuates Aged Gut Dysbiosis and Functional Deficits after Traumatic Brain Injury
粪便微生物群转移可减轻老年肠道菌群失调和脑外伤后的功能缺陷
- 批准号:
10573109 - 财政年份:2023
- 资助金额:
$ 57.35万 - 项目类别: